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ABSTRACT The novel viral vectors PVX-CP AltMV and PVXdt-CP AltMV are superexpressors of the capsid 
protein (CP). These viral vectors were constructed on the basis of the potato virus X (PVX) genome and Alter-
nanthera mosaic virus (AltMV) CP gene. The expression, based on the hybrid viral vectors, is genetically safe, 
since the systemic transport and formation of infective viral particles are blocked. CP AltMV can self-assemble 
into virus-like particles (VLPs) in the absence of genomic RNA. The vectors can be used for the presentation of 
foreign peptides (including epitopes of human pathogens) on the surface of the VLP. The N-terminal extracel-
lular domain (M2e) of the influenza virus A M2 protein and its truncated variant (ΔM2e) were used as model 
heterologous peptides for the construction of the chimeric CP AltMV. Chimeric CP AltMV retains its ability to 
self-assemble into VLP. The epitopes of the M2 influenza virus protein were not eliminated during the process 
of accumulation, polymerization and purification of chimeric VLP AltMV, providing evidence of the stability 
of chimeric VLP with C-terminal heterologous epitopes. It appears that VLP produced by the vectors PVX-
CP AltMV and PVXdt-CP AltMV can be used in the field of biotechnology for the presentation of the epitopes 
of vaccine proteins on their surfaces. The chimeric VLP AltMV with the presented foreign epitopes can be used 
as candidate vaccines.
KEYWORDS potexviruses; viral vector; foreign epitope; chimeric virus-like particles.
ABBREVIATIONS PVX – potato virus X; AltMV – Alternanthera mosaic virus; CP – capsid protein; dt – deletion of 
triple gene block; PVX-CP AltMV – hybrid viral vector based on PVX genome and CP AltMV; M2e – ectodomain 
of influenza A virus M2 protein; ΔM2e – truncated variant of M2e; CP-M2e AltMV, CP-ΔM2e AltMV – chimeric 
CP AltMV with epitope of M2 protein; VLP – virus-like particles; PCR – polymerase chain reaction; NTR – Non-
translated region.
INTRODUCTION
the utilization of plants for the expression and accu-
mulation of foreign (target) proteins (tPs) used in med-
icine, veterinary science, agriculture, and industry is 
one of the most promising directions in bioengineering.
Plant cells are superior to those collected from ani-
mals or microorganisms in terms of both their techno-
logical simplicity and the possibility to simultaneously 
produce a large amount of inexpensive target products, 
and proteins produced from plants are completely safe, 
due to the absence of pathogens that are common to 
humans and plants. the presence of post-translational 
modification systems in plants typically ensures correct 
conformation formation of target proteins through di-
sulfide bonds and glycosylation.
One of the most efficient methods for the rapid pro-
duction of significant amounts of target proteins in 
the cytoplasm of infected cells is the use of autono-
mously replicating recombinant viral vectors. the 
high rate of viral genome replication allows to achieve 
high copy numbers of transcripts from foreign genes 
in the infected cell’s cytoplasm. therefore, the aver-
age efficiency of a viral expression system is higher 
than the efficiency upon stable plant transformation 
or the transient expression using nonviral vectors 
by two orders of magnitude [1, 2]. Viral vectors con-
structed on the basis of plant rnA viruses (tobamo-, 
potex-, como-, bromo-, and potyviruses) are the most 
frequently used. [3].
there are two major strategies for producing target 
proteins using a viral vector:
1) the tP gene is expressed under the control of the 
viral promoter, yielding an individual protein. this can 
be based on the “gene insertion strategy,” when a tP 
gene is placed under the control of the duplicated sub-
genomic promoter (e.g., the coat protein gene [2, 4–6]) 
or on the “gene substitution strategy,” when a viral 
gene (most frequently the coat protein gene and/or the 
genes responsible for viral transport) is substituted for 
the tP [7–11]. this approach facilitates the accumula-74 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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tion of the target protein at quantities amounting to at 
least 10% of the total amount of soluble plant proteins, 
over a short period of time. Vectors based on the phy-
toviral genome have been successfully applied in the 
production of proteins for medical use (including vac-
cine proteins) in plants. this strategy was used to syn-
thesize the hepatitis B virus core protein (HBcAg) and 
calicivirus capsid protein, which are capable of forming 
stable virus-like particles stimulating the humoral and 
cellular immune responses [12, 13];
2) the strategy of “fusion” of the nucleotide se-
quence of the tP gene, or its fragment, and the viral 
gene or its fragment. Here, the viral gene of the capsid 
protein and the tP gene are typically expressed as a 
single translational frame. However, there are limits 
to the size of the inserted foreign sequence. extensive 
polypeptides are usually linked to the principal protein 
via a flexible bridge, via proteolysis sites, via the se-
quence of 2A peptide from the foot-and-mouth disease 
virus, etc. [14–17].
Studies of the molecular mechanisms of the activa-
tion of the adaptive immune response indicate that pep-
tides, rather than entire proteins, are more likely to be 
responsible for the activation of t- and B-lymphocytes 
[18]. Both synthetic and recombinant peptides are un-
stable and possess weak antigenic activity [19]; however, 
binding to high-molecular weight supports with a high 
immunogenicity results in the enhancement of the im-
munogenicity and stability of these peptides [18].
An example of such supports are the capsid proteins 
(cP) of plant viruses, which are capable of forming viral 
and/or virus-like nanoparticles which can be used for 
the presentation of pathogen epitopes on their surface. 
these nanoparticles have a stable and regularly repeat-
ing structure that facilitates the induction of strong cel-
lular and humoral immune responses [20–23].
the strategy was used to construct viral vectors 
that produce viruses with chimeric cP in plants. the 
epitopes of antigens of the Staphylococcus aureus, foot-
and-mouth disease virus, hepatitis c virus, papilloma-
virus, human immunodeficiency virus, influenza virus 
[24–33], and many other viruses (see reviews [3, 34]) 
were presented on the surface of these virions.
However, viral vectors based on full-length genomes 
(capable of systemic transport and formation of infec-
tive viral particles) are considered unsafe for use in bio-
engineering. When producing the target proteins, it is 
impossible to eliminate the probability of penetration of 
recombinant viruses into the environment, followed by 
uncontrolled propagation of the genetic material. 
the capsid proteins of certain animal and plant vi-
ruses retain their ability to form stable capsids, virus-
like particles (VLPs), in the absence of a viral genome. 
the use of VLPs for efficient presentation of epitopes 
foreign to the immune system [21, 35–37] on their sur-
face can resolve the problem of bio-safety as relates to 
vaccine protein production. today, special attention is 
paid to the construction of vector systems that express 
capsid proteins forming VLPs free of any rnA impuri-
ties. Only such VLPs are believed permissible for ap-
plication in bio- and nano-engineering [38, 39].
this study focuses on the construction of a system of 
genetically safe viral vectors based on potex virus ge-
nomes for the production of VLPs that present patho-
gen epitopes on their surface in plants.
EXPERIMENTAL
Media, reagents, enzymes, and 
synthetic oligonucleotides
In this study, we used Escherichia coli XL-1 Blue (Strat-
agene, uSA) and Agrobacterium tumefaciens GV3101 
from the collection of the Department of Virology, 
Moscow State university. the recombinant DnAs were 
cloned in E. coli XL-1 Blue cells through the conven-
tional procedures [40] using restriction endonucleases, 
DnA ligase, and taq and Pfu polymerases (Fermentas, 
Lithuania and Sibenzyme-M, russia). the oligonucle-
otides were synthesized by Sintol (russia). the follow-
ing synthetic oligonucleotides were used for cloning: 
cP AltMV-XhoI-p (ctAGctcGAGAtGtccActc-
cAtttcctcAA), cP AltMV-XbaI-m (cGtctA-
GAttActccGGtGGtGGGAGGtAttGA), 
PVX-r-Avr2-p (tGcAcAGAttttcctAGGcAc), PVX-r-
XhoI-m (AGctctcGAGcttAttcAAAtctctAAG-
GtA),  PVX-3ntr-XbaI-p  (AGcttctAGAc-
tAcGtctAcAtAAccGAcGc), Oligo(dt)24-Kpn-m 
(AGctGGtAcctttttttttttttttttttttttt), 
PVX-Kpn-(dt)12-3ntr-m  (AGctGGtAc-
cttttttttttttAtAttAttcAtAcAAtc), 
PVX-Xba-cpxho-3ntr-p  (AGtctctAGtc-
GAGGcGttcAGGAAcA),  cP  AltMV-evet-
pirn-XbaI-m  (cGtctAGAttAGtttctGAt-
GGtGtttcAccctccGGtGGtGGGAGGtA), 
cP AltMV-M2e-m (tttccAcctctGtcAAGAGt-
GActccGGtGGtGGGAGGtA),  M2e-XbaI-m 
(cGtctAGAttAGtcGGAtGAGtcGttGcAtct), 
M2e-p (tcActcttGAcAGAGGtGGAAAcAc-
cAAtcAGAAAcGAGtGGG), and M2e-m (GtcG-
GAtGAGtcGttGcAtctGcAtccccActcGtt-
tctGAtt). the validity of the obtained constructs 
was verified by automatic sequencing plasmid DnA 
samples at Genotekhnologiya (russia).
PVX-CP AltMV and PVXdt-
CP AltMV vector constructs
Binary hybrid vectors were constructed in several 
stages using intermediate constructs (Ics).reSeArcH ArtIcLeS
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IC 1 – the fragment from the plasmid PVX-201 
containing the 35S promoter, PVX replicon with the 
duplicated subgenomic promoter, but without the 
transcription terminator of the nopaline synthase gene 
(tnos-terminator) at the HindIII/ecorI sites, was 
transferred into the pBIn 19 binary vector.
IC 2 – the AltMV capsid protein gene was obtained 
by Pcr on a matrix of cDnA-copy of the 3’-terminal 
region of the AltMV genomic rnA using primer pair 
cP AltMV-XhoI-p and cP AltMV-XbaI-m and sub-
cloned into the cambia 6963 vector at the XhoI/XbaI 
restriction sites.
IC 3 – For convenient cloning, the XbaI restriction 
site flanking the subgenomic promoter of 25 kDa pro-
tein PVX was substituted for the XhoI restriction site. 
For this purpose, the cDnA fragment of PVX encod-
ing the c-terminal region of the viral polymerase was 
obtained by Pcr on the PVX-201 matrix using the 
PVX-r-Avr2-p and PVX-r-XhoI-m primer pair. the 
synthesized fragment was cloned at the Avr2/XhoI 
sites into the pGeM3-11369(polio)x2 vector contain-
ing the subgenomic promoter of the 25 kDa protein 
gene; the sequence encoding the c-thermal region of 
PVX polymerase and the cP u1 tobacco mosaic virus 
(tMV) with a duplicated poliovirus epitope. the pro-
cedure was used to delete the sequence of the u1 tMV 
cP gene from the pGeM3-11369(polio)x2 vector and 
design the XhoI restriction site at the 3’-terminus of 
the subgenomic promoter of the 25 kDa protein.
IC 4 – three variants of 3’-ntr were obtained by 
Pcr on the PVX-201 matrix using three primer pairs: 
PVX-3ntr-XbaI-p and Oligo(dt)24-Kpn-m were used 
to synthesize 3’-ntr of PVX (A)24; primers PVX-3ntr-
XbaI-p and PVX-Kpn-(dt)12-3ntr-m, to synthesize 3’-
ntr of PVX (A)12; and primers PVX-Xba-cpxho-3ntr-
p and PVX-Kpn-(dt)12-3ntr-m, to synthesize 3’-ntr 
of PVX p/cp(A)12.
Following cleavage by XbaI/Kpn restrictases, the 
synthesized DnA fragments corresponding to differ-
ent variants of 3’-ntr were cloned into the pBlue-
Script II SK+ plasmid at XhoI–(XbaI)–KpnI sites, si-
multaneously with the cP AltMV gene that had been 
removed at a preliminary stage from Ic 2 at the XhoI/
XbaI sites.
IC 5 – the DnA fragment corresponding to cP Alt-
MV with the adjacent 3’-ntr was removed from Ic 4 
at the XhoI/KpnI restriction sites and cloned into Ic 3 
at the XhoI–(KpnI)–SacI sites, simultaneously with the 
DnA fragment that corresponded to the tnos-termina-
tor and had been removed at a preliminary stage at the 
KpnI/SacI sites from the pGeM subclone containing 
the tnos-terminator.
At the last stage of cloning, the DnA fragment from 
Ic 5 at the XhoI/SacI or AvrI/SacI site was transferred 
into the Ic 1 that had undergone prior treatment with 
SalI/SacI or AvrI/SacI restrictase.
Obtainment of vector constructs expressing 
chimeric capsid proteins of AltMV
IC 6 – the cP AltMV gene containing the sequence 
encoding the ΔM2e-variant was obtained by Pcr on 
the matrix of a cDnA copy of the 3’-terminal region of 
AltMV genomic rnA using the cP AltMV-XhoI-p and 
cP AltMV-evetpirn-XbaI-m primer pair, and it was 
subcloned into the cambia 6963 vector at the XhoI/
XbaI restriction sites. the cP AltMV gene encoding the 
full-length М2е domain was obtained by Pcr via three 
stages, using the pair of synthetic oligonucleotides 
М2Е-p and М2Е-m, and two primer pairs (cP AltMV-
XhoI-p and cP AltMV-М2Е-m, cP AltMV-XhoI-p and 
M2e-XbaI-m) and subloned into the cambia 6963 vec-
tor at the XhoI/XbaI restriction sites.
IC 7 – In Ic 5, the sequence of the viral capsid pro-
tein was substituted at the XhoI/XbaI sites for the se-
quences of chimeric capsid proteins from Ic 6.
At the final cloning stage, the DnA fragments from 
Ic 7 at site XhoI/SacI or AvrI/SacI were transferred 
to the Ic 1 that had been preliminarily treated with the 
restrictase SalI/SacI or AvrI/SacI.
Agroinjection
Agrobacteria A. tumefaciens (strain GV3101) were 
transformed by recombinant plasmids using the freeze–
thawing procedure [41]. the agrobacteria containing 
recombinant binary vectors were cultivated overnight 
on a incubator shaker at 280С in an LB medium con-
taining 50 mg/l of rifampicin, 50 mg/l of kanamycin, 
and 25 mg/l of gentamicin. the cells were deposited by 
centrifugation at 4000 g for 5 min and then resuspend-
ed in an agroinjection buffer containing 10 mM of Mes 
(pH 5.5) and 10 mM of MgSO4. Nicotiana benthamiana 
leaves were injected with an agrobacterial suspension 
(OD600 = 0.2) using a needle-free syringe. Following the 
agroinjection, the plants were grown under a daylight 
lamp subjected to 16 h of light per day at a temperature 
of 220С. In order to suppress posttranscriptional gene 
silencing, the agroinjection of plants was performed in 
the presence of the p19 suppressor gene of the tomato 
bushy stunt virus.
Analysis of expression of the AltMV 
capsid protein upon agroinjection
the preparations from agroinjected N. benthamiana 
leaves were homogenized in three-five volumes of the 
extraction buffer (10 mM tris, pH 8.0, containing 5 mM 
eDtA). the obtained suspension was clarified by cen-
trifugation at 12000 g for 15 min. An equal volume of 
denaturating buffer for subsequent application onto 76 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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polyacrylamide gel was added to the supernatant. the 
buffer for applying the samples on SDS-PAGe gel con-
tained 60% of glycerol, 20% of β-mercaptoethanol, 10% 
of sodium dodecyl sulfate, 250 mM tris-Hcl buffer, pH 
6.8, and 1% bromophenol blue. the analyzed samples 
were heated at 950С for 15 min and fractionated by 
electrophoresis in 12% SDS-PAGe gel using the Laem-
mli procedure [42], followed by coomassie r-250 stain-
ing. the chimeric capsid viral proteins synthesized in 
N. benthamiana leaves were identified via Western blot 
analysis as previously described [43], using polyclonal 
antibodies to cP AltMV and/or M2e-epitope and sec-
ondary antibodies conjugated to horseradish peroxi-
dase (Sigma). the reaction products were visualized via 
chemiluminescence, using the ecL system (Amersham 
Biosciences).
Extraction of AltMV capsid proteins from plant tissue
On the sixth - eighth day after agroinjection, the leaf 
material was ground in the extraction buffer (10 mM 
tris, pH 8.0, 5 mM eDtA) in order to achieve a homo-
geneous suspension. the resulting mixture was centri-
fuged at 12000 g for 15 min, followed by the collection 
of the supernatant containing capsid proteins. For the 
polymerization of cP AltMV and formation of VLPs, a 
0.5 M citrate buffer, pH 4.0, was added to the superna-
tant until a concentration of 25 mM was achieved, fol-
lowed by incubation for 40 min at room temperature. 
the pseudovirions from the plant extract were deposited 
by ultracentrifugation at 100 000 g for 120 min, or using 
polyethylene glycol (8% PeG 6000, 2% nacl, 25 mM ci-
trate buffer, pH 4.0). the precipitates were suspended 
in a 25 mM citrate buffer (pH 4.0), incubated for 40 min 
for the correcting polymerization, and then clarified by 
centrifugation at 12000 g for 15 min. the resulting prep-
arations of chimeric VLPs were subjected to an enzyme 
immune assay and electron microscopy analysis.
Electron microscopy
the samples prepared by the conventional negative 
contrast procedure using a 1% uranyl acetate solution 
were viewed on a JeM-1011 transmission electron mi-
croscope (JeOL, Japan). the images were made using 
a Gatan erlangshen eS500W digital camera and Gatan 
Digital Micrograph software × 250000.
RESULTS AND DISCUSSION
Hybrid viral vectors
Potato virus X and the Alternanthera mosaic virus 
belong to the genus Potexvirus (potexviruses),  family 
Flexiviridae. the particles of typical PVX are flexible 
filamentous virions of helical structure with a length 
of 515 nm and a diameter of 13.5 nm. Approximately 
1,300 identical capsid protein subunits form the po-
lar PVX helix with a pitch of 3.6 nm. the viral rnA is 
located between the helix turns; each turn comprises 
8–9 cP subunits. the particles have a hollow central ax-
ial channel with a diameter of 3 nm [44, 45].  An expres-
sion system based on potexvirus genomes was designed 
using the popular vector PVX-201 containing a complete 
cDnA copy of the PVX uK3 genome cloned between the 
35S promoter of the cauliflower mosaic virus (caMV) 
and the tnos-terminator [4]. AltMV  serologically close, 
but not identical, to the papaya mosaic virus (PMV) was 
used as a capsid protein donor [46]. cP PMV differs from 
the cP of the typical representative of  potexviruses 
(PVX) in terms of the former’s ability to form virus-
like particles in vitro with  helical symmetry, without 
the participation of rnA [47]. the data of the electron 
microscopy analysis of cP AltMV preparations indicate   
that the AltMV capsid protein is also capable of  in vitro 
formation of VLPs.
two types of hybrid viral vectors, PVX-cP AltMV 
(complete genome variant) and PVXdt-cP AltMV 
(minireplicon variant), were constructed on the basis of 
the PVX and AltMV genomes. the PVX-cP AltMV ge-
nome is controlled by the 35S promoter and tnos-ter-
minator and contains 5’- and 3’-untranslated regions of 
PVX rnA, the gene of rnA-dependent rnA polymer-
ase of PVX, and the triple block of PVX transport genes. 
the cP AltMV gene is expressed under the control of 
the subgenomic promoter of cP PVX. the PVXdt-
cP AltMV is also controlled by the 35S promoter and 
tnos-terminator and contains 5’- and 3’-untranslated 
PVX rnA regions, and the gene of rnA-dependent 
rnA polymerase of PVX. However, it does not contain 
the triple gene block, like  in the case of the construct 
described in [10]. In viral vectors PVXdt-cP AltMV, 
the gene of the AltMV capsid protein is controlled by 
the subgenomic promoter of the 25 kDa PVX protein.
It is known that, for efficient synthesis of the target 
protein, the viral vector needs to contain a certain set of 
cis-acting elements in the 3’-untranslated region, which 
determine the following: the affinity to replicase, to fa-
cilitate transcription and translation, and to provide a 
maximum expression level of foreign genes. Since the 
3’-terminal cP PVX gene in hybrid viral vectors is sub-
stituted by the cP AltMV gene, three model variants 
of 3’-ntr were used to construct the vectors: 3’-ntr 
of PVX (A)24; 3’-ntr of PVX (A)12; and 3’-ntr of PVX 
p/cp (A)12. the 3’-ntr of PVX (A)12 corresponds to the 
3’-terminal region of the full-length infectious cDnA 
copy of the PVX genome (PVX-201). the 3’-ntr of 
PVX (A)24 does not contain an AtAAAt sequence; how-
ever, the poly(A) tract is increased from 12 to 24 A. the 
3’-ntr of PVX p/cp (A)12 contains the corresponding 
PVX-201 poly(A) tract; however, the 3’-ntr is in-reSeArcH ArtIcLeS
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creased by 60 nucleotides at its 5’-terminus, due to the 
cP PVX gene that is adjacent to the 3’-ntr.
thus, two types of hybrid viral vectors (Fig. 1) were 
constructed on the basis of the PVX genome at the 
first stage: PVX-cP AltMV and mini-vector-replicon 
PVXdt-cP AltMV, with three variants of 3’-ntr for 
each vector. All constructs were cloned into the binary 
pBIn19 vector for further infection of N. benthamiana 
plants with agrobacteria.
Replication of hybrid viral vectors 
in N. benthamiana leaves
the efficiency of the expression of the cP AltMV gene 
using various vectors was determined via the accumu-
lation of the capsid protein in N. benthamiana leaves on 
the sixth - eighth day after agroinjection. It should be 
noted that, in all the constructs under discussion, the 
replication of the hybrid viral vector PVX-cP AltMV 
in N. benthamiana plants led to the accumulation of 
cP AltMV in approximately identical amounts as were 
determined for cP PVX upon mechanical inoculation 
of the virus to plants (over 1 mg per 1 g of green mate-
rial). AltMV is typically accumulated in plants in lower 
concentrations (approximately 340 µg per 1 g of green 
material).
no distinctions were detected in the efficiency of 
cP production when using different 3’-ntr. the 
deletion of the 60 nucleotide 3’-terminal fragment 
from the cP PVX gene did not result in a reduction 
in the cP AltMV level, contrary to the data presented 
in [10]. It can reasonably be assumed that the exist-
ing homology between the 3’-terminal regions of the 
cP PVX and cP AltMV genes is sufficient to provide 
an efficient performance of PVX polymerase. Simi-
lar results, namely, the absence of preference for any 
3’-ntr variant and a similar level of accumulation 
of the recombinant cP AltMV, were also obtained 
upon replication of PVXdt-cP AltMV viral vectors 
(Fig. 2A). Vector constructs with only a single 3’-ntr 
variant (3’-ntr of PVX (A)12) were subsequently used 
(Fig. 1).
the mini-vectors PVXdt-cP AltMV were not su-
perior to the PVX-cP AltMV vectors in terms of ac-
cumulation of the recombinant AltMV capsid protein 
in N. benthamiana leaves on days 6–8 following the 
agroinoculation in the presence of the gene-silencing 
suppressor (the p19 protein gene of the tomato bushy 
stunt virus) (Fig. 2A).
It is known that intercellular and systemic transport 
of PVX in plants is regulated by four genes, including 
the triple gene block (tGB) and cP [4]. no recombinant 
cP AltMV was detected in the systemic, non-agroin-
jected N. benthamiana leaves that were agroinoculated 
with hybrid viral PVX-cP AltMV vectors on days 16–
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Fig. 1. Schematic representation of hybrid viral vectors constructed on the basis of the potato virus X (PVX) genome 
and Alternanthera mosaic virus (AltMV) CP gene. RDRP – gene of viral RNA-dependent RNA polymerase; TGB1, 
TGB2, TGB3 – triple gene block; sgp – sub-genomic promoter are indicated by arrows; CP AltMV– gene of Alternan-
thera mosaic virus capsid protein; М2e – N-terminal extracellular domain of the M2 protein of the influenza virus; ΔM2e 
- truncated variant of the М2e; 35S - promoter for the 35S RNA of CaMV; Tnos - terminator of nopaline synthase; NTR 
- non-translatable region; LB – left border and RB – right border of the T-DNA. The initial polygenomic vector PVX-
CP AltMV and the truncated replicon vector PVXdt-CP AltMV contained DNA fragments encoding full-length native 
CP AltMV. The complete genome chimeric vectors (PVX-CP-M2e AltMV and PVX-CP-ΔM2e AltMV) and chimeric rep-
licon vectors (PVXdt-CP-M2e AltMV, PVXdt-CP-ΔM2e AltMV) encoded chimeric coat proteins: CP-M2e AltMV and 
CP-ΔM2e AltMV. The above constructs were cloned into the binary vector and used to infect plants via agrobacteria. 78 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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20 (Fig. 2B). thus, the substitution of the cP PVX gene 
in recombinant hybrid viral vectors for the cP AltMV 
gene results in disruption of the systemic transport of 
the hybrid virus.
It was demonstrated via electron microscopy analy-
sis of the extracts from N. benthamiana leaves agroin-
oculated with the hybrid viral vectors PVX-cP AltMV 
and PVXdt-cP AltMV that the recombinant capsid 
protein of AltMV can form extensive virus-like parti-
cles (see below), which can be used to present foreign 
epitopes on their surface. A uV absorption spectrum 
within 225–339 nm of the VLP-cP AltMV preparation 
isolated from the plant extract attests to the absence of 
rnA in it (the data are not presented).
When used for presentation of pathogen epitopes, it 
is noteworthy that VLPs with helical symmetry present 
a certain advantage over VLPs with icosahedral sym-
metry; specifically, they possess a greater number of 
subunits per VLP. therefore, it is possible that they can 
present a larger number of pathogen epitopes by chi-
meric cP in VLP.
Construction of hybrid viral vectors expressing 
chimeric capsid proteins of AltMV
the n-terminal domain of the influenza A virus М2 
(М2е) protein and its truncated variant (ΔM2e), which 
are responsible for the triggering of the protective im-
mune response, were used as a model foreign peptide 
for construction of the chimeric cP AltMV [48]. the 
influenza A virus matrix (M2) protein is considered a 
promising candidate for the design of an antiviral vac-
cine, since the amino acid sequence of the ectodomain 
of this protein (M2e) is highly conserved and has re-
mained almost unaltered since the human influenza A 
virus was first isolated in 1933 [49]. A consensus syn-
thetic amino acid sequence of the M2 protein ectodo-
main was proposed on the basis of a computer analysis 
of 55 isolates of the human influenza A virus [50].
Since the conformational structure of cP AltMV is 
still as yet unknown, the search for the optimal inser-
tion site (an insertion site which ensures the presen-
tation of a heterologous epitope on the capsid protein 
surface whilst having a minimal effect on cP confor-
mation without impeding the formation of polymeric 
structures) was carried out using the DnAStar soft-
ware package. Finally, the c-terminal localization of the 
M2e-epitope and the ΔM2e variant within the chimeric 
cP AltMV were selected. the nucleotide sequence of 
the M2e-epitope and the ΔM2e variant was constructed 
on the basis of the corresponding consensus amino acid 
sequence of the n-terminal domain of the influenza A 
virus M2 protein, using the synonymous codons that 
occur most frequently in the genome of the PVX and 
AltMV capsid proteins.
the chimeric cP AltMV genes encoding the full-
length M2 protein ectodomain (23 amino acid residues, 
M2e-epitope), SLLteVetPIrneWGcrcnDSSD, 
and the truncated variant, ΔМ2е (8 amino acid resi-
dues, eVetPIrn) fused to the c-terminus of cP (cP-
M2e AltMV and cP-ΔМ2е AltMV), were obtained by 
Pcr. cloning sequences of chimeric capsid proteins in 
the hybrid viral vectors PVX-cP AltMV and PVXdt-
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cP AltMV were performed to replace the sequences of 
the viral capsid proteins.
thus, four hybrid viral vectors containing the genes 
of the chimeric capsid proteins of AltMV (Fig. 1) were 
constructed on the basis of the PVX genome: PVX-cP-
M2e AltMV and its mini-variant PVXdt-cP-M2e Alt-
MV; PVX-cP-ΔМ2e AltMV and its mini-variant 
PVXdt-cP-ΔМ2e AltMV. these constructs were used 
to transform competent cells of agrobacteria to infect 
N. benthamiana plants.
Expression of chimeric capsid proteins 
of AltMV in N. benthamiana leaves
Hybrid viral vectors based on the PVX genome which 
encode the genes of the chimeric capsid proteins of 
AltMV (cP-М2е and cP-ΔМ2e) were agroinjected into 
N. benthamiana leaves. Six to eight days following the 
agroinjection, the synthesis of chimeric proteins was 
quantitatively assessed via fractionation of the solu-
ble proteins in SDS-PAGe gel and coomassie stain-
ing (Fig. 3A). the chimeric capsid viral proteins were 
identified via a Western blot analysis using polyclonal 
antibodies to cP AltMV or М2е-epitope (Fig. 3B). Same 
as for cP AltMV, no differences in the accumulation of 
chimeric capsid proteins were observed upon replica-
tion of the full-length hybrid viral vector or its mini-
variant. the production of cP-M2e and cP-ΔМ2e de-
pended upon the individual features of the plant, the 
layer a leaf belonged to, and seasonal conditions. nev-
ertheless, it follows from the electrophoregrams shown 
in Fig. 3 that the level of accumulation of the chimeric 
capsid proteins of AltMV (cP-М2е and cP-ΔМ2e) in 
plant leaves is comparable to the level of recombinant 
cP AltMV and is equal to over 1 mg (in some experi-
ments, up to 3 mg) per 1 g of green material.
the chimeric capsid proteins of AltMV with M2e-
epitope and the ΔМ2e-variant, similar to the initial 
capsid protein of AltMV, form extensive virus-like par-
ticles with pH decreasing to 4.0–4.9 under conditions of   
low ionic strength of a solution. A chimeric VLP prepa-
ration can be isolated from the plant extract by ultra-
centrifugation or precipitation with polyethylene glycol. 
the results of the enzyme immune assay and electro-
phoretic and electron microscopy analyses of chimeric 
VLP preparations are shown in Figs. 4, 5. As follows 
from the presented data, epitopes of the influenza A vi-
rus M2 protein are not eliminated during the accumula-
tion, polymerization, and purification, which attests to 
the stability of the chimeric cP AltMV when the for-
eign epitope localizes at the c-terminus. the fact that 
the foreign epitope does not impede the polymerization 
of the chimeric cP AltMV upon c-terminal localization 
indicates the conformational differences between the c-
terminal regions cP AltMV and cP PVX [51].
CP-ΔМ2е AltMV
CP-М2е AltMV
100 nm
100 nm
100 nm
CP AltMV
Fig. 5. Electron micrographs of AltMV VLP and chimeric 
AltMV VLP preparations obtained in N. benthamiana 
leaves. Polymers of CP AltMV were negatively stained 
with a 1% uranyl acetate solution. The bar is 100 nm. 
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CONCLUSIONS
Our study aimed to design a system that could be used 
to present heterologous epitopes (pathogene epitopes) 
on the surface of the virus-like particles formed by the 
capsid protein of the phytovirus. the hybrid viral vec-
tors PVX-cP AltMV and PVXdt-cP AltMV, with a 
number of advantages over the initial PVX and AltMV 
viruses, were constructed on the basis of the PVX ge-
nome and the cP AltMV gene.
1) the level of accumulation of the recombinant cap-
sid protein of AltMV upon agroinjection of N. bentha-
miana leaves with hybrid viral vectors is as high as 1 
mg/g of plant material, which considerably exceeds the 
accumulation upon mechanical inoculation of a natural 
host;
2) the substitution of the cP PVX gene in hybrid 
viral vectors for the cP AltMV gene results in the sup-
pression of systemic transport of the hybrid virus and 
disruption of viral particle formation;
3) the ability to form VLPs is ensured by the feature 
of the AltMV capsid protein; cP PVX is incapable of 
forming VLPs.
the results presented point to the potential applica-
tion of the viral vectors PVX-cP AltMV and PVXdt-
cP AltMV in bioengineering in order to produce vac-
cine proteins in plants. the AltMV capsid protein that 
is accumulated at a high concentration and forms vi-
rus-like particles in the absence of genomic rnA can 
be used for efficient presentation of epitopes of hu-
man and animal infectious agents on the VLP surface. 
chimeric capsid proteins of AltMV with model heter-
ologous peptides, epitopes of the influenza A virus M2 
protein, are also capable of forming stable VLPs. the 
expression system based on the hybrid viral vectors 
PVX-cP AltMV and PVXdt-cP AltMV is genetically 
safe. the use of this vector system allows one to avoid 
both the spontaneous vertical and horizontal transmis-
sion of plant infection and the unregulated spread of 
genetic material into the environment. 
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